Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ: SRPT) has announced a collaboration with GenEdit to develop gene editing therapeutics targeting neuromuscular diseases. Utilizing GenEdit's NanoGalaxy platform, the partnership aims to create effective non-viral delivery systems for genetic medicines. Initial in vivo results show successful delivery to muscle tissue. Sarepta has exclusive rights to license up to four neuromuscular indications. The collaboration could yield up to $57 million in payments for GenEdit, alongside future royalties on product sales, marking a significant advancement in genetic medicine.
Sarepta Therapeutics (NASDAQ:SRPT) has granted equity awards to 35 new employees as an inducement to employment, approved by its Board's Compensation Committee. The awards, totaling options for 35,575 shares and 18,350 restricted stock units (RSUs), were made under the 2014 Employment Commencement Incentive Plan. The options have an exercise price of $71.57 per share, aligning with SRPT's closing price on January 31, 2022.
The options and RSUs will vest gradually over four years, contingent upon continued employment.
Sarepta Therapeutics (NASDAQ: SRPT) announced positive topline results from Part 2 of Study SRP-9001-102, a clinical trial for SRP-9001, a gene therapy for Duchenne muscular dystrophy (DMD). Participants treated with SRP-9001 scored 2.0 points higher on the North Star Ambulatory Assessment compared to matched controls (p=0.0009). The therapy demonstrated a strong safety profile with no new safety signals or serious adverse events. The study, presented at the J.P. Morgan Healthcare Conference, reinforces confidence in SRP-9001's potential as a disease-modifying treatment for DMD.
Sarepta Therapeutics (NASDAQ:SRPT) will present at the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, showcasing topline results from Part 2 of Study SRP-9001-102. This study focuses on the investigational gene therapy SRP-9001 for children aged 4 to 7 with Duchenne muscular dystrophy. The virtual presentation is scheduled for 10:30 a.m. E.T. and will include a Q&A session. The event can be accessed live on Sarepta's investor relations website, where it will also be archived for 90 days.
Sarepta Therapeutics (NASDAQ:SRPT) announced the granting of equity awards to 25 new employees as a material inducement for employment, approved by its Compensation Committee on December 31, 2021. The awards included options to purchase 19,175 shares and 9,900 restricted stock units (RSUs). The stock options have an exercise price of $90.05, equal to the closing price on the Grant Date. The vesting schedule for the options and RSUs is structured to encourage long-term employment, with shares fully vesting by December 31, 2025.
Sarepta Therapeutics (NASDAQ:SRPT) announced the grant of equity awards on November 30, 2021, as part of its 2014 Employment Commencement Incentive Plan. These awards serve as a material inducement to the hiring of 35 employees. In total, the company granted options for 42,225 shares and 21,675 restricted stock units (RSUs). The options have an exercise price of $80.81 per share and vest over a four-year period. Sarepta focuses on precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy, and currently supports over 40 development programs.
Sarepta Therapeutics (NASDAQ:SRPT) has announced a leadership transition, appointing Louise Rodino-Klapac, Ph.D., as head of research and development (R&D) effective immediately. She continues her role as chief scientific officer, following the departure of Gilmore O’Neill, who will serve as a consultant through March 31, 2022. Dr. Rodino-Klapac has been instrumental in the advancement of Sarepta’s gene therapy platform. Under O’Neill’s leadership, the R&D team achieved significant milestones, including the approval of RNA-based therapies for Duchenne muscular dystrophy and the initiation of pivotal trials.
Sarepta Therapeutics (NASDAQ:SRPT) has appointed Dr. Stephen L. Mayo, a distinguished protein engineering expert, to its Board of Directors effective immediately. Dr. Mayo, who currently holds a professorship at Caltech and serves on Merck's board, brings extensive scientific knowledge and business insights. The leadership highlights that Dr. Mayo's expertise will enhance Sarepta's capabilities as it advances its gene therapy pipeline. This strategic addition aims to bolster the company's position in genetic medicine for rare diseases.
Sarepta Therapeutics (SRPT) reported a 37% increase in net product sales for Q3 2021, totaling $166.9 million. Due to strong performance, the company raised its full-year guidance by $40 million, now projecting revenues of $605-$615 million. This marks the 20th consecutive quarter of revenue growth. Sarepta launched two pivotal trials for its therapies targeting Duchenne muscular dystrophy and presented promising data for its gene therapy programs. The company ended Q3 with over $2 billion in cash and equivalents, positioning it for future development.
Sarepta Therapeutics (NASDAQ:SRPT) announced participation in three virtual investor conferences. Senior management will engage in fireside chats at:
- Credit Suisse 30th Annual Healthcare Conference on November 9, 2021 at 12:10 p.m. E.T.
- Barclays Gene Editing & Gene Therapy Summit on November 15, 2021 at 3:00 p.m. E.T.
- Evercore ISI 4th Annual HealthCONx Conference on November 30, 2021 at 1:25 p.m. E.T.
Webcasts will be available on Sarepta’s website, archived for 90 days. The company focuses on precision genetic medicine for rare diseases.